Vesugen
Also known as: Lys-Glu-Asp, KED
Key Facts: Vesugen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Evidence Level
- Preclinical
- Duration
- 10-30 day cycles
What to Expect
A tripeptide bioregulator (Lys-Glu-Asp) targeting vascular tissue. Promotes restoration of blood vessel tissues and normalization of vascular function. Stimulates endothelial cell proliferation markers.
Mechanism of Action
Vesugen stimulates proliferation-associated protein Ki-67 in vascular endothelial cells, counteracting age-related decline. It promotes tissue restoration and normalization of vessel function through direct gene regulatory effects on vascular cells.
Research Summary
Studies in tissue-specific cell cultures from young and old animals showed Vesugen stimulated Ki-67 expression that decreases during aging. Research demonstrates age-associated protective properties in vascular endothelial cell cultures.
Dosing Information
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Vascular bioregulator. Part of Khavinson peptide system for cardiovascular support.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
Related Peptides
Peptides commonly compared with Vesugen or used in similar applications.
Livagen
PreclinicalA tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure and gene expression. Research shows it can decondense heterochromatin and activate ribosomal genes, potentially restoring more youthful gene expression patterns in aging cells.
BioregulatorsOvagen
PreclinicalA tripeptide bioregulator (Glu-Asp-Leu) targeting liver and gastrointestinal tissue. Derived from liver tissue extracts, Ovagen modulates gene expression related to detoxification, antioxidant defense, and hepatocellular repair.
BioregulatorsCortagen
PreclinicalA tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support. Regulates neurotrophic signaling and synaptic stability.
BioregulatorsChonluten
PreclinicalA tripeptide bioregulator targeting respiratory and lung tissue. Supports healthy lung function and stomach lining. Regulates inflammatory and proliferative processes in respiratory epithelium.
BioregulatorsCrystagen
PreclinicalA tripeptide bioregulator supporting immune system function. Demonstrates age-associated immunoprotective properties in spleen tissue. Part of the Khavinson synthesized peptide series.
BioregulatorsProstamax
PreclinicalA peptide bioregulator targeting prostate tissue. One of five highly efficient synthesized peptides developed by Khavinson with demonstrated effects on gene expression and tissue-specific regulation.
BioregulatorsWant updates on Vesugen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.